298 related articles for article (PubMed ID: 28866799)
1. Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.
Hernando S; Herran E; Figueiro-Silva J; Pedraz JL; Igartua M; Carro E; Hernandez RM
Mol Neurobiol; 2018 Jan; 55(1):145-155. PubMed ID: 28866799
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Administration of chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease.
Gartziandia O; Herrán E; Ruiz-Ortega JA; Miguelez C; Igartua M; Lafuente JV; Pedraz JL; Ugedo L; Hernández RM
J Biomed Nanotechnol; 2016 Dec; 12(12):2220-30. PubMed ID: 29372975
[TBL] [Abstract][Full Text] [Related]
3. Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.
Gottschalk CG; Jana M; Roy A; Patel DR; Pahan K
J Neurosci; 2021 Mar; 41(10):2287-2300. PubMed ID: 33514677
[TBL] [Abstract][Full Text] [Related]
4. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.
Dietz GP; Valbuena PC; Dietz B; Meuer K; Müeller P; Weishaupt JH; Bähr M
Brain Res; 2006 Apr; 1082(1):61-6. PubMed ID: 16703672
[TBL] [Abstract][Full Text] [Related]
5. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
6. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
Pak ME; Ahn SM; Jung DH; Lee HJ; Ha KT; Shin HK; Choi BT
J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):712-721. PubMed ID: 31644786
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease.
Wang X; Cui G; Yang X; Zhang Z; Shi H; Zu J; Hua F; Shen X
Brain Res Bull; 2014 Apr; 103():60-5. PubMed ID: 24583079
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease.
Aly AE; Harmon BT; Padegimas L; Sesenoglu-Laird O; Cooper MJ; Waszczak BL
Mol Neurobiol; 2019 Jan; 56(1):688-701. PubMed ID: 29779176
[TBL] [Abstract][Full Text] [Related]
10. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.
Yue P; Gao L; Wang X; Ding X; Teng J
Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332
[TBL] [Abstract][Full Text] [Related]
11. Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's disease.
Revishchin A; Moiseenko L; Kust N; Bazhenova N; Teslia P; Panteleev D; Kovalzon V; Pavlova G
BMC Neurosci; 2016 Jun; 17(1):34. PubMed ID: 27286696
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats.
Bender TS; Migliore MM; Campbell RB; John Gatley S; Waszczak BL
Neuroscience; 2015 Sep; 303():569-76. PubMed ID: 26166725
[TBL] [Abstract][Full Text] [Related]
13. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration.
Gartziandia O; Herran E; Pedraz JL; Carro E; Igartua M; Hernandez RM
Colloids Surf B Biointerfaces; 2015 Oct; 134():304-13. PubMed ID: 26209963
[TBL] [Abstract][Full Text] [Related]
14. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.
Garbayo E; Ansorena E; Lana H; Carmona-Abellan MD; Marcilla I; Lanciego JL; Luquin MR; Blanco-Prieto MJ
Biomaterials; 2016 Dec; 110():11-23. PubMed ID: 27697668
[TBL] [Abstract][Full Text] [Related]
15. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
eNeuro; 2017; 4(1):. PubMed ID: 28303260
[TBL] [Abstract][Full Text] [Related]
16. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.
Aly AE; Waszczak BL
Expert Opin Drug Deliv; 2015; 12(12):1923-41. PubMed ID: 26289676
[TBL] [Abstract][Full Text] [Related]
17. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
18. Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.
Requejo C; Ruiz-Ortega JA; Bengoetxea H; García-Blanco A; Herrán E; Aristieta A; Igartua M; Pedraz JL; Ugedo L; Hernández RM; Lafuente JV
Mol Neurobiol; 2017 Dec; 54(10):7722-7735. PubMed ID: 27844282
[TBL] [Abstract][Full Text] [Related]
19. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Tanriover G; Seval-Celik Y; Ozsoy O; Akkoyunlu G; Savcioglu F; Hacioglu G; Demir N; Agar A
Folia Histochem Cytobiol; 2010 Sep; 48(3):434-41. PubMed ID: 21071351
[TBL] [Abstract][Full Text] [Related]
20. Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures.
Hernando S; Nikolakopoulou P; Voulgaris D; Hernandez RM; Igartua M; Herland A
Fluids Barriers CNS; 2022 Mar; 19(1):22. PubMed ID: 35300705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
